Navigation Links
Mach One Completes Note Exchange
Date:1/22/2009

BELGIUM, Wis., Jan. 22 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), a biological solutions company that develops products that produce a positive long term benefit to the agricultural and consumer market, announced today that it has completed its Subordinated Note Swap of $1.5 million with an Investor.

Mach One issued the Original Note to facilitate the equipment purchase for its first production facility in Wisconsin. The Original Note had an amortization schedule that started after the completion of the equipment purchase. The new board upon review of that part of the capital structure did not see the need to start amortization during the Wisconsin facility startup stage so it proposed exchanging the Original Note for a Zero Coupon Convertible Note similar in structure to the Note issued in the Pacific Rim Foods Ltd. transaction.

Monte B. Tobin, Chairman and Chief Executive Officer of Mach One, said, "We are pleased that our board has taken an active role in assisting the company in matching its capital structure to its business model. We continue to execute on our business plan and are pleased with this recent capital change which when combined with the capital provided by Pacific Rim Foods Ltd, and the recent $500,000 and $1.5 million capital placement will allow Mach One to move forward on execution of its business model."

Tad Ballantyne, Director, said, "We are pleased to have a strategic Investor who recognizes the benefits to both parties of the Note exchange. We look forward to the strategic Investor's participation as a board member along with the addition of another board member from the announced Ceres Organic transaction. Both these anticipated board members have extensive experience in the 'healthy food' sector which is part of our mission of building a global company focusing on the 'health benefits to man and animal.' Execution of both capital formation and board oversight are important components of building a successful public company."

Safe Harbor Statement

This press release contains forward-looking information. Readers are cautioned not to place undue reliance on any such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties which are disclosed in the Company's SEC reports. These risks and uncertainties could cause actual results to differ materially from those currently anticipated or projected. Readers are encouraged to view the Company's risks identified under the caption "Risk Factors" in the S-1 Registration Statement of the Company as Amended filed with the Securities and Exchange Commission on September 18, 2008.


'/>"/>
SOURCE Mach One Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial
2. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
3. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
4. Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
5. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
6. BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)
7. NeoStem Completes $500,000 Private Placement With Strategic Investor
8. Lilly Completes Cash Tender Offer for ImClone Systems
9. China Medical Technologies Completes the Development of EGFR Molecular Diagnostic Kits
10. Accera, Inc. Completes $35 Million Series C Financing
11. OncoMed Pharmaceuticals Completes Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a provider ... MegaMatcher Automated Biometric Identification System (ABIS) , ... multi-biometric projects. MegaMatcher ABIS can process multiple complex ... any combination of fingerprint, face or iris biometrics. ... SDK and MegaMatcher Accelerator , which ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
Breaking Biology News(10 mins):